Wistar scientists have developed a new type of bispecific T cell engager, or BTE, that is effective against ovarian cancer in ...

The trial is enrolling adult women with recurrent ovarian cancer after at least two previous therapies. Credit: Jo Panuwat D / Shutterstock.com. (Jo Panuwat D / Shutterstock.com.) Anixa Biosciences ...

Results of a study led by researchers at Roswell Park Comprehensive Cancer Center show that combining two types of immunotherapy - engineered T cells that secrete bispecific T cell engagers (BiTEs) ...

Ovarian cancer has long proved difficult to treat. Could the answer lie within the disease itself? Discover how synthetic ...

Hua-Ying Fan, PhD, hopes that her team's latest discovery could help the almost 21,000 people who are expected to receive an ovarian cancer diagnosis this year. Fan's team at The University of New ...

Ovarian cancer remains one of the most difficult-to-treat diseases. With all our advances in screening and molecular profiling, it still maintains the worst death-to-diagnosis rate among gynecologic ...